Rznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics
Rznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics
PR Newswire
SEONGNAM, South Korea, Aug. 23, 2026
SEONGNAM, South Korea, Aug. 23, 2026 /PRNewswire/ -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining Lilly Gateway Labs (LGL) in San Diego, California.
Lilly Gateway Labs is a best-in-class innovation hub designed to empower biotechnology companies to advance groundbreaking science by providing access to wet lab facilities and opportunities to engage with Lilly scientists and executives. Lilly Gateway Labs is part of Lilly Catalyze360, alongside Lilly Ventures, Lilly ExploR&D, and Lilly TuneLab, which together support biotech innovation by providing access to strategic capital, lab space and technology, and research and development capabilities.
Through its entry into Lilly Gateway Labs, Rznomics plans to accelerate candidate discovery and development across its target gene database bank comprising over 200 disease targets, while simultaneously driving long-term efforts to establish global clinical infrastructure for its lead pipelines, expand global strategic partnerships, and recruit top-tier R&D researchers in the U.S.
"Joining Lilly Gateway Labs in San Diego represents a meaningful milestone for Rznomics' proprietary RNA platform," said Seong-Wook Lee, CEO of Rznomics. "We intend to advance the development and commercialization of our RNA therapeutics by active collaboration with the global biotech ecosystem."
About Rznomics Inc.
Rznomics is a clinical-stage biopharmaceutical company based in South Korea focused on developing RNA-based gene therapies. The company's proprietary trans-splicing ribozyme platform enables precise RNA editing and has broad applicability across multiple indications. The company signed a research collaboration and license agreement with global pharmaceutical company Eli Lilly and Company in May 2025 for the development of a novel RNA editing therapeutic and listed on the KOSDAQ market in December 2025. (KOSDAQ 476830)
For more information, please visit www.rznomics.com
SOURCE Rznomics
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The 10 Best Companies to Invest in Now
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
4 Stocks to Buy Before They Rise Further
The Top Funds for a Simpler Retirement Portfolio
United States